Argenx, NL0010832176

Argenx stock heads into the open after a 2.6 percent gain

Published on 09/04/2026 at 14:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

At the close on September 3, 2026, Argenx stock finished at USD 1,055.37 on the Nasdaq, up 2.61 percent, while trading within a tight intraday range. Analyst commentary kept a positive tone on the name ahead of today’s session.

Fotorealistisches Laborpanorama: Wissenschaftler in weißen Kitteln begutachten leuchtende Antikörper-3D-Modelle auf Bildschirmen, Stahltische mit Laborgeräten im Hintergrund
Argenx NL0010832176 Forscher analysieren im modernen Biopharma-Labor leuchtende Antikörper-Strukturen auf großen Monitoren, Illustration mit AI erstellt.

Argenx stock closed at USD 1,055.37 on the Nasdaq on September 3, 2026, rising 2.61 percent from the previous session. The move came as the shares held within a relatively narrow band during the day, with investors digesting recent positive analyst views. Today the stock enters the new session with that fresh gain as a starting point and no company-specific event formally scheduled in the near term based on available calendars.

September 3, 2026 in numbers

Market data show that Argenx finished the last completed Nasdaq session at USD 1,055.37, after adding 26.86 points, which corresponds to a 2.61 percent daily increase. Intraday, the quote page indicates that the stock’s day range remained close to the closing level, pointing to contained volatility rather than wide swings in either direction. While detailed volume figures are not broken out in the snapshot, the session still delivered a clear positive close for shareholders. For reference, the broader Nasdaq Composite index moved only modestly on the same date, meaning Argenx outperformed the wider market on September 3, 2026.

Analyst commentary has recently stayed constructive on Argenx, with firms such as William Blair and Jefferies maintaining buy ratings and setting targets above the latest closing price, reinforcing a supportive backdrop into the latest session. In one report, Jefferies reiterated a buy stance together with a price target of USD 1,215.00, underlining confidence in the stock’s medium-term potential even after the recent advance. That context helped frame the 2.61 percent rise on September 3, 2026 as part of an ongoing period of favorable sentiment rather than an isolated jump.

Today’s session and near-term calendar

Heading into today’s trading, there is no confirmed Argenx-specific item such as an earnings release, shareholder meeting, or ex-dividend date recorded for September 4, 2026 in major earnings and corporate calendars. Over the next several trading days, available sector and economic schedules likewise do not list an Argenx event, so attention is likely to stay on broader healthcare and biotechnology developments and general risk appetite. With recent analyst support already in place and a clear gain from the last session, market participants can place the USD 1,055.37 close and 2.61 percent rise from September 3, 2026 at the center of their orientation as trading resumes today.

The session on September 3, 2026 in numbers

  • Stock: Argenx SE (ISIN NL0010832176)
  • Close Nasdaq, September 3, 2026: 1,055.37 USD
  • Daily change: +2.61 percent
  • Day range: close near intraday high and low, narrow band USD
  • Reference index Nasdaq Composite, September 3, 2026: modest move compared with Argenx’s 2.61 percent gain
  • 52-week range: within the established 52-week band, with the latest close closer to the upper part USD
  • Today: No Argenx-specific event recorded for September 4, 2026 in major calendars
More on this stock

Further coverage of Argenx stock

All news, analyses and price data on Argenx stock in one topic overview.

Disclaimer...

en | NL0010832176 | ARGENX | boerse | 70054547 | bgmi